Search
Organogenesis Holdings Inc
ORGOAdd to Watchlist
2.360USD
-0.080-3.28%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
303.67MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-3.28%
5 Days
-2.88%
1 Month
-4.84%
6 Months
-49.08%
Year to Date
-54.44%
1 Year
-44.47%
Key Figures
2.440Open
2.480High
757.98KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.59%Turnover Ratio
2.440Prev. Close
2.340Low
1.07MTurnover
LossP/E Static
1.24P/B
0.00%Div Yield TTM
0.55%ROA
7.07752wk High
1.21Volume Ratio
-937.00KNet Profit
128.67MShares
-0.1105EPS TTM
1.32Beta
-5.97%ROE
2.04052wk Low
5.74%Amplitude
30.77%Gross Margin
303.67MMarket Cap
-0.42Reward/Risk
3.88%Risk Rate
TradingKey Stock Score of Organogenesis Holdings Inc
Currency: USD Updated: 2026-07-02Key Insights
Organogenesis Holdings Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 81 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 3.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Organogenesis Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Organogenesis Holdings Inc Highlights
StrengthsRisks
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 30.25% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 564.17M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is -21.36, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 70.97M shares, decreasing 7.21% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 56.65K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.32.
Analyst Rating
Based on
2
analysts
Hold
Current Rating
3.000
Target Price
+22.95%
Upside Space
Organogenesis Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Organogenesis Holdings Inc Info
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
Ticker SymbolORGO
CompanyOrganogenesis Holdings Inc
CEOGillheeney (Gary S)
Websitehttps://investors.organogenesis.com
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Organogenesis Holdings Inc (ORGO)?
The current price of Organogenesis Holdings Inc (ORGO) is 2.36.
What is the symbol of Organogenesis Holdings Inc?
The ticker symbol of Organogenesis Holdings Inc is ORGO.
What is the 52-week high of Organogenesis Holdings Inc?
The 52-week high of Organogenesis Holdings Inc is 7.08.
What is the 52-week low of Organogenesis Holdings Inc?
The 52-week low of Organogenesis Holdings Inc is 2.04.
What is the market capitalization of Organogenesis Holdings Inc?
The market capitalization of Organogenesis Holdings Inc is 303.67M.
Is Organogenesis Holdings Inc (ORGO) currently rated as Buy, Hold, or Sell?
According to analysts, Organogenesis Holdings Inc (ORGO) has an overall rating of signal_hold, with a price target of 3.00.
What is the Earnings Per Share (EPS TTM) of Organogenesis Holdings Inc (ORGO)?
The Earnings Per Share (EPS TTM) of Organogenesis Holdings Inc (ORGO) is 0.16.